TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26162946

Group type: EXPERIMENTAL
Intervention: High-dose therapy with rosuvastatin (5 mg for 4 weeks, then 10 mg for 8 weeks)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Low-dose therapy with rosuvastatin (2.5 mg for 12 weeks)
Number of subjects: 111
Study: 25842456

Group type: EXPERIMENTAL
Intervention: New 2-step etch & rinse adhesive and a new nano-filled ormocer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Composite (control)
Number of subjects: 50
Study: 22198596

Group type: EXPERIMENTAL
Intervention: Caries exams by trained, calibrated examiners
Number of subjects: 437
Study: 19997018

Group type: COMPARATOR
Intervention: CHO beverage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHO + protein beverage (CHO + Pro)
Number of subjects: 12
Study: 18617126

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (TFP) - Duragesic 50 microg/h, applied approximately 10 hours before induction of general anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) programmed in the PACU
Number of subjects: 30
Study: 15975304

Group type: EXPERIMENTAL
Intervention: Breviscapine intravenously dripped for 2 treatment courses
Number of subjects: 76

Group type: COMPARATOR
Intervention: Amlodipine, captopril/uropidil
Number of subjects: 76
Study: 19753721

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 120
Study: 16021880

Group type: EXPERIMENTAL
Intervention: Combination of didanosine plus stavudine plus nevirapine with hydroxyurea
Number of subjects: 22

Group type: COMPARATOR
Intervention: Combination of didanosine plus stavudine plus nevirapine without hydroxyurea
Number of subjects: 22
Study: 8614136

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 243

Group type: COMPARATOR
Intervention: CyA alone
Number of subjects: 243

Group type: COMPARATOR
Intervention: CyA+LI
Number of subjects: 243

Group type: COMPARATOR
Intervention: CyA group
Number of subjects: 243
Study: 29503305

Group type: EXPERIMENTAL
Intervention: Chuma na Uchizi intervention (cash transfers, access to savings account, life-skills training)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (receiving outpatient care)
Number of subjects: 101
Study: 27603344

Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 210
Study: 24879492

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 116
Study: 23094269

Group type: EXPERIMENTAL
Intervention: Submerging vital roots
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control area (no submerged roots)
Number of subjects: 10
Study: 20427778

Group type: COMPARATOR
Intervention: Vitamin E (800 IU daily)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Pioglitazone (30 mg daily)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 247

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 247
Study: 17991257

Group type: EXPERIMENTAL
Intervention: Standard practice plus monitoring of depth of anaesthesia with M-Entropy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard clinical practice
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 72
Study: 15898476

Group type: EXPERIMENTAL
Intervention: Points condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: No-points condition
Number of subjects: 10
Study: 12242596

Group type: EXPERIMENTAL
Intervention: Fluoxetine as the experimental drug
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fluoxetine as the control drug
Number of subjects: 103
Study: 9819017

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (with HCTZ 12.5 mg increased to 25 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nifedipine GITS 30 mg (increased to 60 mg and 90 mg)
Number of subjects: 140
Study: 7707420

Group type: EXPERIMENTAL
Intervention: Individualized breast cancer risk counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: General health counseling (control)
Number of subjects: 200
Study: 2547410

Group type: EXPERIMENTAL
Intervention: Fluconazole (50 mg daily for 21-28 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (before fluconazole therapy)
Number of subjects: 18
Study: 871601

Group type: EXPERIMENTAL
Intervention: Ultrasonic grey-scale image
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other type of ultrasonic image
Number of subjects: 0
Study: 30415083

Group type: EXPERIMENTAL
Intervention: Multifaceted quality improvement intervention including case management, reminders, educational materials, workshops, and audit and feedback reports.
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 1624
Study: 27483481

Group type: EXPERIMENTAL
Intervention: Action planning
Number of subjects: 7399

Group type: EXPERIMENTAL
Intervention: Reward
Number of subjects: 7399

Group type: COMPARATOR
Intervention: Thank you (control)
Number of subjects: 7399
Study: 25346329

Group type: EXPERIMENTAL
Intervention: Lecture and discussion plus case-based learning (n = 35)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional lecture and discussion (n = 66)
Number of subjects: 101

Group type: COMPARATOR
Intervention: CPE nurses (n = 59)
Number of subjects: 101
Study: 23020923

Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 21695251

Group type: EXPERIMENTAL
Intervention: Replication-defective Ad5 gag/pol/nef vaccine
Number of subjects: 0
Study: 19229545

Group type: EXPERIMENTAL
Intervention: 7 days minimal‐residue (low fibre intake) pre‐operative diet (n = 42)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Mechanical bowel preparation the day before the operation (n = 41)
Number of subjects: 83
Study: 17240581

Group type: EXPERIMENTAL
Intervention: Cervical length measurement with a cut-off value of ≤ 2.5 cm
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Internal os diameter measurement
Number of subjects: 200
Study: 12547889

Group type: EXPERIMENTAL
Intervention: Insulin lispro (0.1 units/kg body wt)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Regular insulin (0.1 units/kg body wt)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 11

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 11
Study: 10872995

Group type: EXPERIMENTAL
Intervention: Feldspathic ceramic inlays (Vita Mark II)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Glass ceramic inlays (Dicor MGC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both types of inlays (Feldspathic and Glass ceramic)
Number of subjects: 16
Study: 9432302

Group type: EXPERIMENTAL
Intervention: Patients with unstable angina pectoris
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study: 1549030

Group type: EXPERIMENTAL
Intervention: Protocol A (2% grade increment)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Protocol D (8% grade increment)
Number of subjects: 9
Study: 4025217

Group type: EXPERIMENTAL
Intervention: Ba-wei-wan (hachimijiogan)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Discontinuation of Ba-wei-wan
Number of subjects: 24
Study: 31542473

Group type: EXPERIMENTAL
Intervention: Biportal endoscopic decompressive laminectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Microscopic decompressive laminectomy
Number of subjects: 64
Study: 29309314

Group type: EXPERIMENTAL
Intervention: Prone traction group
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Supine traction group
Number of subjects: 125

Group type: COMPARATOR
Intervention: PT only group
Number of subjects: 125
Study: 27464321

Group type: EXPERIMENTAL
Intervention: Swedish massage therapy (SMT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Light touch control
Number of subjects: 47
Study: 24843973

Group type: EXPERIMENTAL
Intervention: Combination electroacupuncture anesthesia (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular general anesthesia (group A)
Number of subjects: 60
Study: 22640930

Group type: EXPERIMENTAL
Intervention: 2.5 g/d n-3 PUFAs
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 1.25 g/d n-3 PUFAs
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: n-3 PUFAs
Number of subjects: 138
Study: 20850381

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus dexrazoxane
Number of subjects: 205

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 205
Study: 18235121

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/d
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Imatinib 600 mg/d
Number of subjects: 147

Group type: COMPARATOR
Intervention: Both doses (400 mg/d and 600 mg/d)
Number of subjects: 147
Study: 15783259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proven effective therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo trials
Number of subjects: 0
Study: 12020263

Group type: EXPERIMENTAL
Intervention: Budipine 20 mg, 3 times daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 10217608

Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 252

Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 252
Study: 7883776

Group type: EXPERIMENTAL
Intervention: Mesna administration (Arm A: i.v. in equal doses 15 min before and 4 h and 8 h after ifosfamide; Arm B: three equivalent doses 15 min before (i.v.) and 4 h (i.v.) and 8 h (p.o., double dose); Arm C: i.v. in two equal doses 15 min before and 4 h after).
Number of subjects: 122
Study: 2204854

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate aspirated from the anterior chamber prior to wound closure
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sodium hyaluronate not aspirated from the anterior chamber
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups (aspirated and not-aspirated)
Number of subjects: 99
Study: 43585

Group type: EXPERIMENTAL
Intervention: methyl-salazosulphapyridine (125 mg x 3 daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: salazosulphapyridine (1 g x 3 daily)
Number of subjects: 53
Study: 31682972

Group type: EXPERIMENTAL
Intervention: LPS administration
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher baseline inflammatory markers
Number of subjects: 120
Study: 31685496

Group type: EXPERIMENTAL
Intervention: 25° head-up position
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 1000
Study: 30261836

Group type: EXPERIMENTAL
Intervention: HeartMan mHealth system
Number of subjects: 120
Study: 28827261

Group type: EXPERIMENTAL
Intervention: McGrath video laryngoscope
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 2000
Study: 26637340

Group type: EXPERIMENTAL
Intervention: Usual care plus a 12-week supervised exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual outpatient care alone
Number of subjects: 0
Study: 24028354

Group type: EXPERIMENTAL
Intervention: Medication reviews performed by a physician
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Physicians' attitudes toward the intervention
Number of subjects: 199
Study: 21712483

Group type: EXPERIMENTAL
Intervention: Hamstring tendon autograft (semitendinosus and gracilis)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patellar tendon autograft
Number of subjects: 64
Study: 18850550

Group type: EXPERIMENTAL
Intervention: AcrySof SN60AT (spheric lenses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: AcrySof IQ SN60WF (aspheric lenses)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Natural crystalline lenses
Number of subjects: 69
Study: 17027369

Group type: EXPERIMENTAL
Intervention: BMP15 gene mutations screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12779351

Group type: EXPERIMENTAL
Intervention: Nephrectomy followed by treatment with interferon alfa‐2b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment with interferon alfa‐2b alone
Number of subjects: 0
Study: 10845018

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.4% oxybuprocaine
Number of subjects: 90
Study: 9170825

Group type: COMPARATOR
Intervention: Dinoprostone vaginal tablets
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal tablets
Number of subjects: 60
Study: 8362631

Group type: EXPERIMENTAL
Intervention: 0.2 second argon laser trabeculoplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1 second argon laser trabeculoplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (0.1 second and 0.2 second)
Number of subjects: 0
Study: 4027102

Group type: EXPERIMENTAL
Intervention: MST Continus 20 mg (oral morphine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: i.m. morphine 10 mg
Number of subjects: 80
Study: 30907200

Group type: EXPERIMENTAL
Intervention: cGCE
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29546298

Group type: EXPERIMENTAL
Intervention: 3 L semiskimmed milk/wk
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual milk consumption (baseline median: 140 mL/d; IQR: 40‐240 mL/d)
Number of subjects: 78
Study: 26893546

Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 30 mg/kg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 60 mg/kg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine 100 mg/kg/day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Multimatrix mesalamine (all doses)
Number of subjects: 52
Study: 26689369

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using multiple agglomerative hierarchical clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using normal distribution model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using normal regression model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation (MI) using predictive mean match
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian analysis models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Bayesian analysis models
Number of subjects: 0
Study: 21773858

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 163
Study: 20610636

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency (serum 25(OH)D concentration < 30 ng/mL)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: LL-37 concentrations
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Correlation of LL-37 concentrations
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Serum vitamin D status
Number of subjects: 95
Study: 18331221

Group type: EXPERIMENTAL
Intervention: 10% water solution of sucrose (CHO; 4 kcal/kg body mass)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Equal volume of water (control)
Number of subjects: 14
Study: 15980352

Group type: COMPARATOR
Intervention: 873140 50 mg to 800 mg single dose
Number of subjects: 70

Group type: COMPARATOR
Intervention: 873140 200 mg to 800 mg repeat dose (BID for 8 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Food consumption with 400 mg dose
Number of subjects: 70

Group type: COMPARATOR
Intervention: 873140 200 mg BID
Number of subjects: 70

Group type: COMPARATOR
Intervention: 873140 800 mg BID
Number of subjects: 70
Study: 12680865

Group type: EXPERIMENTAL
Intervention: Mite allergen‐impermeable mattress encasings
Number of subjects: 810

Group type: COMPARATOR
Intervention: Placebo mattress encasings
Number of subjects: 810
Study: 10868525

Group type: EXPERIMENTAL
Intervention: BM+PBPC
Number of subjects: 27

Group type: COMPARATOR
Intervention: BM
Number of subjects: 27
Study: 7854545

Group type: EXPERIMENTAL
Intervention: Patients with Parkinson's disease
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study: 3291223

Group type: EXPERIMENTAL
Intervention: Cs monotherapy (8 to 10 mg/kg/d)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Combination therapy (Cs, azathioprine, and prednisolone or Cs and azathioprine)
Number of subjects: 110
Study: 766879

Group type: EXPERIMENTAL
Intervention: Wistar RA 27/3 vaccine
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Cendehill strain live attenuated vaccine
Number of subjects: 1525
Study: 31192834

Group type: EXPERIMENTAL
Intervention: Lavender oil aromatherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 60
Study: 28283752

Group type: EXPERIMENTAL
Intervention: Preoperative immune-modulating diet (IMD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard liquid diet (SLD)
Number of subjects: 30
Study: 26904891

Group type: EXPERIMENTAL
Intervention: Calcium alginate wound dressings with hemostatic gauze pad (Group C)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Gauze pad (Group A)
Number of subjects: 997

Group type: COMPARATOR
Intervention: Calcium alginate wound dressings (Group B)
Number of subjects: 997
Study: 23932803

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 83953

Group type: EXPERIMENTAL
Intervention: Other cholesterol-lowering medications
Number of subjects: 83953

Group type: COMPARATOR
Intervention: No cholesterol-lowering agents (Control group)
Number of subjects: 83953
Study: 21531082

Group type: EXPERIMENTAL
Intervention: Patients with AN before weight gain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with AN after weight gain
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy control group (CG)
Number of subjects: 30
Study: 18155058

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg bolus dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine with epinephrine (5 mcg/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both Lidocaine and Lidocaine with epinephrine
Number of subjects: 50
Study: 20617345

Group type: EXPERIMENTAL
Intervention: Commercially-based drink (Moove™)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hospital-prepared supplements
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Commercially available supplements
Number of subjects: 59

Group type: COMPARATOR
Intervention: Hospital supplements
Number of subjects: 59
Study: 16136764

Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12002666

Group type: EXPERIMENTAL
Intervention: Fixed combination of latanoprost 0.005% and timolol 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol monotherapy
Number of subjects: 0
Study: 10408664

Group type: EXPERIMENTAL
Intervention: Gutter frame
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Zimmer frame
Number of subjects: 27

Group type: COMPARATOR
Intervention: Unaided walk
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rollator frame
Number of subjects: 27
Study: 8071762

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G
Number of subjects: 169

Group type: COMPARATOR
Intervention: Procaine penicillin G
Number of subjects: 169
Study: 2847079

Group type: EXPERIMENTAL
Intervention: 40 mg IM daily of purified bovine brain gangliosides (Cronassial)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 100 mg IM daily of purified bovine brain gangliosides (Cronassial)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 4445714

Group type: EXPERIMENTAL
Intervention: Ice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untuned short wave diathermy
Number of subjects: 0
Study: 31282101

Group type: EXPERIMENTAL
Intervention: VTE prophylaxis continued
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Change in VTE risk category
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Change in bleed risk category
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: VTE RAMs usage
Number of subjects: 351
Study: 29584916

Group type: EXPERIMENTAL
Intervention: Mechanical lysis of fibrotic tissue in the epidural space
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hyaluronidase and corticosteroid methylprednisolone acetate during the procedure
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 48
Study: 27424614

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both SP and AZ
Number of subjects: 200
Study: 24927471

Group type: EXPERIMENTAL
Intervention: Internet treatment (NET)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 52
Study: 22616078

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks and intranasal budesonide for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 0
Study: 19898966

Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam (LEV)
Number of subjects: 52
Study: 17852670

Group type: EXPERIMENTAL
Intervention: Very high molecular weight glucose polymer solution
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low molecular weight glucose polymer solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sugar-free flavoured water (control)
Number of subjects: 8
Study: 16156505

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 141

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 141
Study: 11788414

Group type: EXPERIMENTAL
Intervention: Diuretic (spironolactone: 100 mg/day, 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (normovolemia)
Number of subjects: 8